Drug intelligence / Profile preview

TCX-301

Development stage: Unknown
Lead developer: BlueSphere Bio
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TCX-301 is an investigational TCR-T cell therapy developed by BlueSphere Bio. It is currently in the discovery phase and is being explored for the treatment of neoplasms, specifically solid tumors. As a TCR-T cell therapy, it involves engineering a patient's own T cells to express specific T-cell receptors (TCRs) that can recognize and target tumor-associated antigens on cancer cells, thereby enhancing the immune system's ability to attack solid tumors. The drug has not yet entered clinical trials or received regulatory approval.

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on TCX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCX-301.

Explore the full profile